series HPLC equipped with a diode array detector using a Supelco Discovery C18 column (5 µm, 250 mm x 10 mm). The product was eluted using a linear gradient of 1% D/min, with a flow rate of 5 mL/min, where the solvent system used was: A (MilliQ water + 0.01% TFA) and D (acetonitrile + 0.08% TFA). Typically, a 0-40% acetonitrile over 40 min gradient was used; however gradient systems were adjusted according to the elution profiles and peak profiles obtained from the analytical RP-HPLC chromatograms. Fractions were analysed by LCMS. Pure fractions were pooled, and lyophilised.
Protein Quantification IGF-II analogues were quantified by comparing analytical RP-HPLC C4 profiles with profiles of standard Long™Arg3IGF-I preparations, on an Agilent 1100 series RP-HPLC using the procedure described by Denley et al. 3 
IGF-II Sequence and Analogues
A Y R P S E T L C G G E L V D T L Q V C G D C D L A L L E T Y C A T P A K S E
Synthesis of coumaryl amino acid building blocks
Coumaryl amino acid building block (Cou) shown below was synthesised following the methods outlined by Brun et al. 4 and Wang et al. 5 . 
Ethyl magnesium malonate
An aqueous solution of magnesium chloride hexahydrate (MgCl 2 6H 2 O) (3.05 g, 10 ml, 1.5 M) was added to an aqueous solution of ethyl potassium malonate (5.10 g, 10 ml, 3 M). The resulting solution was stirred at rt for 30 min. The reaction mixture was diluted with isopropanol (200 ml) and the mixture was stirred at rt for a further 30 min. The mixture was then filtered and the filtrate concentrated in vacuo to give ethyl magnesium malonate (4.21 g, 98%) as a white crystalline solid. The product dried under vacuum and used without further purification. 1 
1-Benzyl 6-ethyl 2-(((benzyloxy)carbonyl)amino)-4-oxoheptanedioate
Cbz-Glu-OBn (10.98 g, 30.0 mmol) was dissolved in anhydrous THF (4 mL/mmol) and CDI (5.27 g, 32.5 mmol) was slowly added, the solution was stirred at rt for 2 h under a nitrogen environment. Ethyl magnesium malonate (4.7 g, 16.0 mmol) was added and reaction was stirred under a nitrogen environment at rt for a further 16 h. The reaction mixture was extracted with diethyl ether (3 x 50 mL) and washed with saturated aqueous NaHCO 3 (3 x 50 mL), water (2 x 50 mL) and brine (3 x 50 mL), dried over Na 2 SO 4 and concentrated in vacuo. The resulting oil was purified by silica column chromatography (1:1 PE:EtOAc) to give the β-ketoester (12.4 g, 95%) as a white waxy solid. mp 52-59 °C. 1 
L-(7-Hydroxycoumarin-4-yl) ethylglycine trifluoroacetate salt
The β-ketoester (2.4 g, 5.5 mmol) was slowly added to a stirring solution of resorcinol (3.0 g, 27.0 mmol) in methanesulfonic acid (9.0 mL, 0.14 mol). The solution was stirred vigorously at rt for 120 min an then diluted with cold ether (200 mL). The mixture was cooled in a dry ice/acetone bath for 30 min and the precipitate was isolated by filtration, dissolved in water, and the resulting solution was filtered and lyophilised. The resulting residue was purified by semi-preparative RP-HPLC to give the coumaryl amino acid (517 mg, 28%) as an offwhite solid. mp > 220 °C.
[α] 23 D = 24.18° (c. 1.0, 1 M HCl). 1 H NMR (600 MHz, DMSO -d6 , δ) ppm: 9.23 (br s, OH, 1H), 7.66 (d, J = 8.7 Hz, ArH, 1H), 6 .85 (dd, J = 8.6, 1.7 Hz, ArH, 1H), 6 .72 (d, J = 1.8 Hz, ArH, 1H), 6.07 (s, CH 2 CCHCO, 1H), 3.56 -3.12 (m, NHCHCH 2 CH 2 , 1H), 3.01 -2.67 (m, CH 2 , 2H), 2.15 -1.85 (m, CH 2 , 2H). 13 
(S)-2-((tert-Butoxycarbonyl)amino)-4-(7-hydroxy-2-oxo-2H-chromen-4-yl)butanoic acid (mono-Boc) and (S)-2-((tert-Butoxycarbonyl)amino)-4-(7-((tert-butoxycarbonyl)oxy)-2-oxo-2H-chromen-4-yl)butanoic acid (diBoc)
A solution of the coumaryl amino acid (87 mg, 0.23 mmol) in 5% aqueous NaHCO 3 /dioxane (1:1 v/v) (20 mL) was cooled in an ice bath and Boc anhydride (0.542 g, 2.4 mmol) was added. The reaction was stirred on ice for 1 h then allowed to warm to rt over 16 h. The reaction mixture was acidified to a pH of 3 with 10% (w/v) aqueous citric acid (8 mL) and the solution was extracted with EtOAc (3 x 20 mL), washed with water (3 x 50 mL), brine (3 x 50 mL), dried over Na 2 SO 4 and concentrated in vacuo. The resultant oil was dissolved in a 30% aqueous acetonitrile and lyophilised to give a mixture of the Nα-Boc protected coumaryl amino acid (76 mg, 90%) and the di-Boc protected coumaryl amino acid (8 mg, 8%) as an off-white solid in a ratio of 10:1. MonoBoc from the mixture: 1 
Peptide Synthesis
Procedure for Fmoc-based peptide synthesis (Fmoc-SPPS) Automated peptide synthesis was carried out on a Liberty Microwave Peptide Synthesiser (CEM Corporation) using the Fmoc/tBu strategy 6, 7 . Deprotection: The Nα-Fmoc group was deprotected during each cycle by treatment of the resin with 20% v/v piperidine in DMF containing HOBt (0.10 M) for 30 s, followed by a second deprotection for 3 min. A maximum microwave power of 60 W and the maximum temperature was set to 50 °C for both deprotections. Amino acid couplings: The Nα-Fmoc protected amino acid in DMF (5 equiv, 0.20 M), HATU in DMF (4.5 equiv, 0.45 M) and DIPEA in NMP (10 equiv, 2.0 M) were added to the resin and subjected to 25 W microwave irradiation for 6 min. Each coupling was performed twice with a maximum temperature set to 50 °C for both couplings. The exception was Fmoc-Arg(Pbf)-OH, which was coupled for 25 min at rt, followed by coupling for 5 min at 25 W microwave irradiation and the maximum temperature was set to 50 °C for both couplings.
On completion of the synthesis, a solution comprised of TFA: TIPS: DODT: water (92.5: 2.5: 2.5: 2.5 v/v/v/v) was added to the resin-bound peptide (10 mL/250 mg resin) and the mixture was shaken at rt for 3 h. The resin beads were filtered and the filtrate concentrated to approximately 2 mL under a stream of nitrogen. Ice cooled diethyl ether (40 mL) was added, and the precipitate isolated by centrifugation. The solid material was washed with ice cooled diethyl ether (3 x 40 mL), dissolved in a 30% aqueous acetonitrile containing 0.1 % TFA and lyophilised, followed by purification by RP-HPLC as described above.
Procedure for manual peptide synthesis:-in situ neutralisation Boc SPPS 8 Manual peptide synthesis was performed using the in situ neutralisation Boc SPPS methodology. 8 Deprotection: The Nα-Boc group was removed by treatment with TFA (neat) (2 x 1 min) followed by flow washing of the resin with DMF for 30 s. Amino acid coupling: The Nα-Boc protected amino acid (4 equiv) was pre-activated with a solution of HBTU in DMF (3.8 equiv, 0.38 M) and DIPEA (neat) (20 equiv) for 2 min at rt. The activated solution was added to the resin and the mixture was shaken for 10 min at rt. The solution was drained and the resin flow washed with DMF for 30 s. with the exception of the Nα-Boc protected coumaryl amino acid (Boc-GluCou-OH) (1.2 equiv), which was pre-activated with a solution of HBTU in DMF (1.1 equiv, 0.4 M) and DIPEA (neat) (5 equiv) for 2 min at rt. The activated solution was added to the resin and the mixture was shaken at rt for 18 h. All coupling reactions were monitored via the Kaiser test 9 for primary amines, and where applicable the acetaldehyde/chloranil test 10, 11 for secondary amines was used.
Immediately prior to resin cleavage, the Nα-Boc group was removed by two successive treatments with TFA (neat) for 1 min. The resin was flow washed with DMF (30 s), DCM (30 s), diethyl ether (30 s) and dried under vacuum for 30 min. The resin-bound peptide was cleaved using anhydrous HF and p-cresol (9:1 v/v) with stirring at 0 °C for 1 h. The HF was evaporated, ice cooled diethyl ether (40 mL) was added, and the precipitate isolated by centrifugation. The solid material was washed with ice cooled diethyl ether (3 x 40 mL), dissolved in a 30% aqueous acetonitrile solution containing 0.1 % TFA and lyophilised, followed by purification by RP-HPLC, as described above.
Confirmation of coupling and deprotection reactions:
Kaiser resin test 9 -A qualitative confirmation test was carried out after each coupling or deprotection reaction using the Kaiser test for free primary amino groups. The test involved sampling approximately twenty resin beads and treating these with 1:1:1 v/v/v of 5% (w/v) solution of ninhydrin in ethanol, phenol (80 g) in ethanol (20 mL); and 0.001 M aqueous KCN (2 mL) in pyridine (98 ml)). The mixture was heated at 100 °C for 5 min. A positive test was denoted by an intense blue coloration of the beads, indicating the presence of a free amino group. Where the test was positive, the Nα-protected amino acid was coupled again under the same conditions.
Acetaldehyde/chloranil resin test 10, 11 -A qualitative confirmation test was carried out after each coupling or deprotection reaction using the chloranil test for free secondary amino groups The test involved sampling approximately twenty resin beads and treating these with a 2% (v/v) solution of acetaldehyde in DMF (25 µL) followed by the addition of of a 2% (w/v) solution of chloranil in DMF (25 µL). A positive test was denoted by a an dark blue/green coloration of the beads, indicating the presence of a free amino group Where the test was positive, the Nα-protected amino acid was coupled again under the same conditions. Solutions were stored in the fridge and were kept for a maximum of 1 week.
Procedure for solid phase extraction (SPE)
The crude peptide mixture was isolated using a solid phase extraction (SPE) cartridge (Alltech, C18LP, 600 mg). The cartridge was prepared by washing with MeOH (5.0 mL) and equilibrated with 5% aqueous acetonitrile containing 0.1% TFA (10.0 mL). The ligation mixture was diluted with water and acidified with TFA if necessary to give a pH of 3, and loaded onto the prepared SPE cartridge at a rate of approximately 2 mL/min. Salts and non-binding contaminants were eluted with 5% aqueous acetonitrile containing 0.1% TFA (10.0 mL) and the crude peptide was eluted on washing the cartridge with 50% aqueous acetonitrile containing 0.1% TFA (10.0 mL). Fractions containing the desired peptide were combined and lyophilised.
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Procedure for oxidative folding/disulphide bond formation
Oxidative folding of the IGF-II peptides was carried out as described by Delaine et al. 12 . Specifically, the purified peptide (4.0 mg/mL) was dissolved in a buffer consisting of 8.0 M urea, 0.10 M Tris and 40 mM glycine containing 20 mM dithiothreitol (DTT). The solution was incubated at rt for 1 h and reduction of any disulphide adducts was monitored by analytical RP-HPLC. After 1 h the reduced solution was rapidly diluted with refolding buffer (1.0 M Tris-HCl, 2.0 mM EDTA, pH 9.1 and sterilised through 1.0 m filter) to give a solution with a final concentration of 2.5 M urea, 0.7 M Tris, 12.5 mM glycine, 2.0 mM EDTA, 0.50 mM DTT, 1.25 mM 2-hydroxyethyldisulfide (2-HED) and a final protein concentration of 0.10 mg/mL This reaction mixture was slowly stirred at rt and formation of the folded IGF-II protein was monitored by analytical RP-HPLC. The reaction was determined complete when no more of the reduced peptide remained, typically after 120 min. The reaction mixture was quenched with conc. HCl to give a pH of 3. The acidified solution was filtered through a 0.45 µM syringe filter and the filtrate purified by semi-preparative RP-HPLC on an HP 1100 series HPLC. Cysteine alkyl thioester linked resin was elongated using the Boc-SPPS protocol described in Section 3.2 to give the resin-bound IGF-II (1-46) thioester. The resin was cleaved with HF and the resulting crude peptide ( Figure  S1A ) was dissolved in a 5% aqueous acetonitrile containing 0.1% TFA and purified by semi-preparative RP-HPLC to afford the IGF-II (1-46) thioester (12.5 mg, 7%) as a white solid (Figure S1B IGF-II (47-67) resin-bound peptide was synthesised on a 0.10 mmol scale from Tentgel® S RAM resin using the Fmoc-based SPPS approach described in Section 3.2. The crude peptide ( Figure S2A ) was dissolved in a 5% aqueous acetonitrile containing 0. Cysteine alkyl thioester linked resin was elongated using the Boc-SPPS protocol described in Section 3.2 to give the resin-bound IGF-II (Thz-46) thioester. The resin was cleaved with HF and the resulting crude peptide ( Figure S5A ) was dissolved in a 5% aqueous acetonitrile containing 0.1% TFA and purified by semi-preparative RP-HPLC to give the IGF-II (Thz-46) thioester (12.3 mg, 11%) as a white solid ( Figure S5B) Figure S5C ). Cysteine alkyl thioester linked resin was elongated according to the Boc-SPPS protocol described in Section 3.2 to give the resin-bound F28Cou IGF-II (Thz-46) thioester. The resin was cleaved with HF and the resulting crude peptide ( Figure S6A ) was dissolved in a 5% aqueous acetonitrile containing 0.1% TFA and purified by semipreparative RP-HPLC to afford the F28Cou IGF-II (Thz-46) thioester (11.8 mg, 3%) as a white solid ( Figure S6B) Figure S6C ). The pH of the solution was adjusted to 6.9 using aqueous NaOH (10 M and 2 M), the reaction mixture was sparged with Ar (10 s) and shaken at rt for 1 h. The products were isolated using SPE according to the procedure described in Section 3. 
Synthesis of C-terminal IGF-II (47-67) fragment
a) Fmoc-SPPS b) TFA/TIPS/DODT
Three fragment synthesis of the native IGF-II protein (IGF-II (3 Fragment))
IGF-II (1-67) HPO 4 , 487 µL), pH of the solution was adjusted to 6.9 using aqueous NaOH (10.0 M and 2.0 M) and shaken at rt for 1 h. MeONH 2 HCl (8.1 mg, 97 µmol, 0.20 M) was then added, the pH of the solution was adjusted to 3.9 with aqueous HCl (5.0 M), the reaction mixture was shaken at rt for 6 h. The pH of the solution was adjusted to 6.8 with aqueous NaOH (10.0 M and 2.0 M) and the N-terminal IGF-II (1-20) thioester (3.9 mg, 1.6 µmol, 3.37 mM) was added. The reaction mixture was shaken at rt for 47 h. The products were isolated using SPE according to the procedure described in Section 3.2 and purified by semi-preparative RP-HPLC to give the native IGF-II peptide (0.44 mg, 4%) as a white solid. The native IGF-II peptide (0.44 mg, 0.058 µmol) was subsequently folded as detailed in Section 4 to give the native IGF-II protein (25 µg, 6%) as a white solid ( Figure S10A) Figure S10B ). Analytical data for the one-pot three fragment synthesis of the native IGF-II protein is summarised in Figure S9 . Figure  S13B ). Analytical data for the one-pot three fragment synthesis of the F19Cou IGF-II protein is summarised in Figure S11 and Figure S12 . Figure  S16B ). Analytical data for the one-pot three fragment synthesis of the F19Cou IGF-II protein is summarised in Figure S14 and Figure S15 . 
Three fragment synthesis of the F19Cou IGF-II protein
Three fragment synthesis of the F28Cou IGF-II protein using native chemical ligation
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6 Competition binding assays
Materials
Long TM Arg 3 IGF-I and human IGF-II were purchased from Novozymes GroPep Pty Ltd. (Adelaide, South Australia). Greiner Lumitrac 600 96-well plates were purchased from Omega scientific (Tarzana, USA). The DELFIA ® europium-labeling kit and DELFIA ® enhancement solution were purchased from PerkinElmer Life Sciences. EuIGF-II was produced as described by Denley et al. 3 according to the manufacturer's instructions. The anti-IGF-1R antibody 24-31 was a kind gift from Prof. K. Siddle (Cambridge, UK). P6 IGF-1R cells (BALB/c3T3 cells overexpressing the human IGF-1R) 13 were a kind gift from Prof. R. Baserga (Philadelphia, PA). 
Competition binding assay buffers
Lysis
Procedure for competition binding assays
The binding of IGF-II analogues to the IGF-1R were measured essentially as described by Denley et al. 3 . Briefly, P6 IGF-1R cells were serum-starved for 4 h and then lysed in lysis buffer (see recipe above) for 1 h at 4 °C. Lysates were centrifuged for 10 min at 3,500 rpm, then an aliquot (100 μL) was added per well to a white Greiner Lumitrac 600 96-well plate previously coated with anti-IGF-1R antibody 24-31 14 . Europium labelled IGF-II (EuIGF-II) (100 μL) with a fluorescent count of 50,000 was added to each well along with increasing concentrations of unlabelled competitor and then the plate was incubated for 16 h at 4 °C. The next day, the wells were washed four times with TBST buffer (see recipe above), then twice with water, and then DELFIA enhancement solution (100 μL/well) was added and the plate was incubated at rt for 10 min. Time-resolved fluorescence of the EuIGF-II was measured using 340 nm excitation and 612 nm emission filters with a Perkin Elmer VICTOR X5 Multilabel Plate Reader (Waltham, MA, U.S.A). IC 50 values were calculated, using GraphPad Prism 6.01, by curve-fitting with a one-site competition model. The baseline used to calculate all IC 50 values was set at the % bound/total value of the highest competing IGF-II concentration. Assays were performed in triplicate at least three times, unless otherwise stated.
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Experimental details for Fluorescence Resonance Energy Transfer (FRET)
Experimental materials
FRET experiments were performed on a Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, CA, USA), using Spectrosil quartz micro cuvettes (100 µL) (Starna) with a 10 mm pathlength at 25 °C, at a pH of 7.0. The excitation wavelength was set to 280 nm and emission spectra were collected between 290 to 600 nm with a scan speed of 600 nm/min. Excitation and emission slit widths were set to 5 nm. Each single spectrum was averaged from three consecutive scans. All solvents, buffers and reagents used were of spectroscopic grade or higher. If spectroscopic grade was not available then solutions and solvents were filtered through a 0.22 µm filter before use.
Procedure for FRET experiments (native IGF-II, F19Cou IGF-II, F28Cou IGF-II in presence of sIGF-1R)
Solublised immunocaptured receptor (sIGF-1R) was prepared according to the procedure described by Surinya et al. 15 and used as a 0.20 µM solution in 0.10 M sodium phosphate buffer (pH 7.2). The IGF-II proteins (synthetic native IGF-II (3 fragment), F19Cou IGF-II and F28Cou IGF-II) were dissolved in 10 mM HCl. FRET experiments were performed by titrating the synthetic native IGF-II (3 Fragment) (0.20 μM; 1.7 μL) or the F19Cou IGF-II protein (0.20 μM; 1.7 μL) against the sIGF-1R (0.20 μM; 100 µL). FRET experiments for the F28Cou IGF-II protein were performed by titration of the F28Cou IGF-II protein (0.19 μM; 1.6 μL) against the sIGF-1R (0.19 μM; 91 µL). After each addition the solution was manually mixed, incubated at rt for 30 min and then spectra after excitation at 280 and 320 nm were recorded. Each IGF-II analogue was added until the protein and sIGF-1R were present in an equimolar ratio.
Procedure for control experiments (native IGF-II, F19Cou IGF-II, F28Cou IGF-II in absence of sIGF-1R)
The IGF-II proteins (synthetic native IGF-II (3 fragment), F19Cou IGF-II and F28Cou IGF-II) were dissolved in 10 mM HCl. Control experiments were carried out under the same conditions as the FRET experiments by titrating the synthetic native IGF-II (3 Fragment) (0.20 μM; 1.7 μL, F19Cou IGF-II protein (0.20 μM; 1.7 μL) or F28Cou IGF-II protein (0.19 μM; 1.6 μL) into buffer (in 0.10 M sodium phosphate buffer (pH 7.2). After each addition the solution was manually mixed, incubated at rt for 30 min and then spectra after excitation at 280 and 320 nm were recorded. 260  300  340  380  420  460  500  540  580   0   40   80   120   160   200   240   280   250nm  255nm  260nm  265nm  270nm  275nm  280nm  285nm  290nm  295nm  300nm  305nm  310nm  315nm  320nm  325nm  330nm  335nm  340nm  345nm  350nm  355nm  360nm  365nm  370nm  375nm 
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Summary of results from FRET experiments
